Familial adenomatous polyposis and other polyposis syndromes

被引:2
|
作者
Holinski-Feder E. [1 ,2 ]
Morak M. [1 ,2 ]
机构
[1] Medizinisch Genetisches Zentrum München, München 80335
[2] Medizinische Klinik, Campus Innenstadt, LMU München
来源
Der Gastroenterologe | 2010年 / 5卷 / 1期
关键词
APC; FAP; MAP; MUTYH; Polyposis coli;
D O I
10.1007/s11377-009-0342-y
中图分类号
学科分类号
摘要
The number of adenomas allows the clinical differentiation of familial adenomatous polyposis into the classical (FAP), attenuated (AFAP), and atypical (ATFAP) forms. Mutations in the APC gene are found in 80% of FAP patients, with inheritance being autosomal dominant. Mutations in MUTYH (MUTYH-associated polyposis, or MAP) follow a recessive inheritance and clinically dominate AFAP. MAP is associated with adenomas, but hyperplastic polyps and serrated adenomas can also be prevalent. Extraintestinal manifestations are associated with FAP. The recurrence risk for FAP is 50% and is below 1% for MAP. Hyperplastic polyposis syndromes (HPS) can show a familial occurrence; mutation analysis of the polyp tissue allows preliminary subdivision into cases with mutations of either BRAF or KRAS and cases with no mutation in either of these genes. The genetic predisposition of HPS in the germline is thus far unknown. The genetics of juvenile polyposis has been established; hamartomatous polyposis syndromes (Peutz-Jeghers and Cowden syndromes) show a 50% mutation detection rate. Especially in hamartomatous polyposis syndromes, the risk for extraintestinal cancers needs to be considered. © 2009 Springer Medizin Verlag.
引用
收藏
页码:7 / 15
页数:8
相关论文
共 50 条
  • [41] Chemoprevention of familial adenomatous polyposis
    Lynch, Patrick M.
    FAMILIAL CANCER, 2016, 15 (03) : 467 - 475
  • [42] The history of familial adenomatous polyposis
    Steffen Bülow
    Terri Berk
    Kay Neale
    Familial Cancer, 2006, 5 : 213 - 220
  • [43] Attenuated Familial Adenomatous Polyposis
    Eizuka, Makoto
    Toya, Yosuke
    Kosaka, Takashi
    Oizumi, Tomofumi
    Morishita, Toshifumi
    Kasugai, Satoshi
    Yanai, Shunichi
    Sugai, Tamotsu
    Matsumoto, Takayuki
    INTERNAL MEDICINE, 2023, 62 (18) : 2651 - 2654
  • [44] FAMILIAL ADENOMATOUS POLYPOSIS COLI
    Boeren, K.
    Vankan, Y.
    Perdieus, D.
    JBR-BTR, 2011, 94 (03): : 112 - 113
  • [45] Management of Familial Adenomatous Polyposis
    Gautam Mankaney
    Carole Macaron
    Carol A. Burke
    Current Treatment Options in Gastroenterology, 2021, 19 (2) : 198 - 210
  • [46] MANAGEMENT OF FAMILIAL ADENOMATOUS POLYPOSIS
    SPIGELMAN, AD
    HODGSON, SV
    THOMSON, JPS
    BAILLIERES CLINICAL GASTROENTEROLOGY, 1992, 6 (01): : 75 - 94
  • [47] HEPATOBLASTOMA AND FAMILIAL ADENOMATOUS POLYPOSIS
    GARBER, JE
    LI, FP
    KINGSTON, JE
    KRUSH, AJ
    STRONG, LC
    FINEGOLD, MJ
    BERTARIO, L
    BULOW, S
    FILIPPONE, A
    GEDDEDAHL, T
    JARVINEN, HJ
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (20) : 1626 - 1628
  • [48] Familial adenomatous polyposis in China
    Yang, Jun
    Liu, Qing Wei
    Li, Liang Wen
    Wang, Qiang Zhi
    Hong, Min
    Dong, Jian
    ONCOLOGY LETTERS, 2016, 12 (06) : 4877 - 4882
  • [49] Treatment of familial adenomatous polyposis
    Kim, HR
    Kim, DY
    Kim, YJ
    6TH CONGRESS OF THE ASIAN FEDERATION OF COLOPROCTOLOGY, 1997, : 9 - 12
  • [50] SULINDAC IN FAMILIAL ADENOMATOUS POLYPOSIS
    TONELLI, F
    VALANZANO, R
    LANCET, 1993, 342 (8879): : 1120 - 1120